Clinical Trial

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

Name: DLL3-Targeted PET/CT in Neuroendocrine Carcinoma — clinical trial record (NCT07458906)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.

Trial Details

NCT Number	NCT07458906
Lead Sponsor	The First Affiliated Hospital of Xiamen University
Conditions	DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer
Enrollment	60 participants
Start Date	2025-12-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-09